Doctor Alberto Cordero

Doctor Alberto Cordero

IMED Elche Hospital, Elche (Spain)

Member of:

Interventional cardiologist involved in cardiovascular prevention and treatment. Research on acute coronary syndromes, secondary prevention and lipids.

Presentations Articles

Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome

Event: ESC Congress 2024

Topic: Lipids

Session: Lipids in heart disease

Access

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

Event: ESC Congress 2024

Topic: Drug therapy

Session: Lipids in heart disease

Access

The determinant role of high-density lipoprotein cholesterol on the recovery of left ventricle ejection fraction after acute coronary syndromes

Event: ESC Congress 2023

Topic: Lipids

Session: Risk factors and prevention: lipids (4)

Access

HDLc levels have a protective effect for in-hospital mortality in Non-STEMI but not in STEMI patients.

Event: ESC Congress 2023

Topic: Lipids

Session: Risk factors and prevention: lipids (3)

Access

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

Event: ESC Preventive Cardiology 2023

Topic: Public Health and Health Economics, Other

Session: Late-Breaking Science session

Access

We need a generalised approach to improve impact at the population level

Event: ESC Preventive Cardiology 2023

Topic: Secondary Prevention

Session: Managing cardiovascular risk: precision medicine for the individual patient or a better generalised approach at the population level?

Access

Differential prognosis of patients candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Platelets and more

Access

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 2

Access

Cholesterol remnants distribution in patients admitted for acute coronary syndrome

Event: ESC Congress 2022

Topic: Lipids

Session: Role of lipids in clinical setting

Access

Predictors of no-reflow in patients with myocardial infarction and ST-segment elevation treated with primary angioplasty

Event: ESC Congress 2022

Topic: Complications

Session: STEMI

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Alberto Cordero

Biography

Contributor content

Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

The determinant role of high-density lipoprotein cholesterol on the recovery of left ventricle ejection fraction after acute coronary syndromes

HDLc levels have a protective effect for in-hospital mortality in Non-STEMI but not in STEMI patients.

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

We need a generalised approach to improve impact at the population level

Differential prognosis of patients candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Cholesterol remnants distribution in patients admitted for acute coronary syndrome

Predictors of no-reflow in patients with myocardial infarction and ST-segment elevation treated with primary angioplasty

ESC 365 is supported by

Doctor Alberto Cordero Follow

Biography

Contributor content

Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

The determinant role of high-density lipoprotein cholesterol on the recovery of left ventricle ejection fraction after acute coronary syndromes

HDLc levels have a protective effect for in-hospital mortality in Non-STEMI but not in STEMI patients.

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

We need a generalised approach to improve impact at the population level

Differential prognosis of patients candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Cholesterol remnants distribution in patients admitted for acute coronary syndrome

Predictors of no-reflow in patients with myocardial infarction and ST-segment elevation treated with primary angioplasty

ESC 365 is supported by

Doctor Alberto Cordero